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Abstract
Although current numbers of non-Caucasian CF patients are small, collectively they represent sizeable groups and increasingly
more is becoming known about the spectrum of mutations in the CFTR gene in different populations. As such it is important to
acknowledge that there will be certain sociocultural challenges in interacting with and managing such patients. This paper explores
such developments and considers some of the current and future challenges facing those who treat the disease. Techniques applied
in other illness contexts for establishing and maintaining effective patient–professional relationships, reviewing patient education,
resolving treatment conflicts and improving adherence are discussed, as are the implications for future research.
 2003 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Engaging individuals in modern health care systems
depends on their intrinsic health beliefs. These not only
vary over time and depend on gender, socio-economic
status and education, but also stem from other values,
cultural and spiritual, which influence how patients’
define and perceive their health (e.g. health as; ‘not ill’,
the absence of disease, leading a socially and emotion-
ally healthy life and being physically fit) w1x. Implica-
tions of poor health can have great cultural significance
and thus have major implications for how patients access
services, interact with health care professionals and
adhere to treatment. Patient information initiatives and
in-patient care are also culturally influenced.
It is argued that cystic fibrosis (CF) is so rare outside
populations of European descent, that screening should
not be offered to these groups w2x. Yet, identification of
an increasing number of genetic mutations in different
populations (Fig. 1), has led others to consider whether
or not CF has been under-reported in certain groups,
being mis-diagnosed as chronic pulmonary infection,
malnutrition, tuberculosis, or failure to thrive w3x. In
some multi-ethnic countries significant differences in
prognosis and clinical status have been found. In the
USA, patients of African–American decent, have sig-
nificantly poorer nutritional status and pulmonary func-
tion than their Caucasian counterparts w4x. In South
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Africa, Cape Coloured children became infected with
Pseudomonas aeruginosa infection significantly earlier
than those of European decent and had a worse 5-year
survival rate w5x. Although socio-economic factors were
implicated in both studies, ethnicity and under-recogni-
tion were also linked.
In the UK people from many ethnic backgrounds may
have CF, for example, Asians, particularly those whose
families originate from northern India (Sikhs and Hin-
dus) Pakistan and Bangladesh (Muslims) and Jews
(both Ashkenazi and non-Ashkenazi). Whilst numbers
may currently be small, the introduction of national CF
screening programmes could raise incidence rates, par-
ticularly in multi-ethnic areas. The ‘strength’ of religious
beliefs varies within these groups, just as in others,
ranging from the non-practising to the fanatical. Con-
sequently, whilst it is wrong to assume that there will
necessarily be cultural barriers to treating Muslims and
Jews with CF, as management needs a multi-systemic
approach, carers need to be aware of potential obstacles
and negotiate how these can be overcome.
2. Challenges
There are four potentially important and inter-linked
aspects of managing CF that may present teams with
sociocultural challenges; establishing and maintaining
patient–professional relationships, patient education,
adherence to treatment and care of the dying and death.
2.1. Patient–professional relationships
The basis for effective treatment is good patient–
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Fig. 1. Distribution of known CFTR mutations amongst different ethnic populations (reproduced with kind permission of Garry Cutting M.D.,
Johns Hopkins, Baltimore MD, USA).
professional relationships. It is important to continually
reflect on how differing sociocultural beliefs and values
affect the establishment of these and the maintenance
of the boundaries between them. Increasing access to
health services for individuals’ from ethnic minority
groups is a national priority in the UK. It is important
that people feel able to engage with service providers
and are motivated to do so. CF team members, them-
selves will come from a variety of different ethnic and
religious backgrounds. At times this too may need to be
reflected on if strong patient–professional are to be
formed. Ultimately it is this that enables effective liaison
and mutual learning and so, CF team members need to
feel comfortable asking questions about different socio-
cultural beliefs (as do all health carers), if they are to
become truly ‘culturally informed’. This rarely results
in offence being caused and indeed, in most cases would
probably be viewed positively or even necessary.
Using family members as interpreters is inappropriate
as it is crucial to try and communicate directly with
each individual to properly hear ‘their views’. As such,
team members need to be trained in how to properly
use interpreting services if good relationships are to be
maintained over, what is usually, long periods of time.
Discussion of how cultural values may impinge on
treatment, for example, issues of gender and touch and
taking detailed family histories, can only truly take place
within a trusting professional therapeutic relationship if
difficulties are to be resolved or negotiated.
2.2. Patient education
Whilst language barriers can usually be overcome,
when combined with the conflicting views of some
parents about Western medicine, for example Asians,
explaining CF to children may become difficult w6x. It
has been reported that, just like other patients in the
UK, some young Asians with CF enter adulthood
knowing little about the condition. CF-related problems
such as decreasing lung function, infertility and poor
mobility, can raise many cultural issues for Asian adults.
Although not all want arranged marriages, these too can
present dilemmas which are rooted in perceptions of
‘acceptability’, parents being reluctant to seek out part-
ners for their children for fear of them being rejected.
This largely depends on how much parents understand
CF and communicate the seriousness of the disease to
prospective parents-in-law (i.e. its treatment and longer-
term implications). If this is minimised there is the
potential to create unrealistic expectations of female
patients in their new role as wife or daughter-in-law w6x.
Considering family dynamics and discussing these
and the impact of CF openly, is vital for teams. Having
a range of CF literature in different languages may be
difficult to prioritise at a local level, however, co-
ordinating such resources nationally may be less oner-
ous. Equally, where appropriate, involving the support
of local religious or spiritual leaders and groups may be
helpful in facilitating discussion and understanding,
particularly where aspects of treatment potentially con-
travene certain beliefs or values.
2.3. Adherence to treatment
Whilst there is no doubt that advances in CF treatment
have significantly improved patients’ longevity and
QoL, the burden of care has also undeniably increased.
Introducing new therapies and treatments to patients and
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the extent to which they adhere to what is prescribed,
will again depend on their relationships with CF team
members and how treatment is negotiated. In order to
consider how cultural beliefs may impact on adherence
rates, carers may need to spend greater time ensuring
that explanations about treatment rationales are properly
conveyed and understood.
Dietetic management poses many challenges for dif-
ferent ethnic and religious groups (e.g. during religious
periods of fasting and the need to avoid certain foods)
and many excellent reviews of these exist w7x. In CF
management there are some particular challenges for
Muslims and Jews. Periods of religious fasting for
people may need to be negotiated and compromises
reached. Pancreatic enzyme replacement therapy is cen-
tral to the nutritional management of CF. Capsules
containing porcine-derived digestive enzymes are taken
orally with all meals and snacks and without clear
guidance from spiritual leaders, this can be problematic
for some patients. Whilst less commonly problematic,
the prescription of some nutritional supplements and
certain vitamins also need to be considered.
Case example
A 17-year-old male patient, who was a devout
Muslim, had been under dietetic review for poor
weight gain. As the assessment progressed, it
became evident that he had stopped taking enzyme
replacement capsules (Creon) on discovering they
were porcine-derived. Despite the fact that the
pharmaceutical company issues a routine statement
from the London Central Mosque Trust & Islamic
Cultural Centre, stating that Creon can be taken
by Muslims (on the grounds that no alternative
exists), the patient’s detailed knowledge of the
Holy Qur’aan was such that he still questioned
taking it. Considerable discussion took place with
the team dietitian, focussing on compromise, the
lack of an alternative enzyme replacement thera-
pies and the effect of non-adherence on the
patient’s long-term health. Guidance and discus-
sion took place with another spiritual leader, the
local Mufti, with whom the patient had close ties1
with and much respect for. His consideration and
subsequent permission was sufficient for the
patient to accept the therapy. He began to gain
weight shortly after recommencing Creon.
In-patient care too can pose significant sociocultural
wNote: The Mufti (spiritualyreligious leader) is the person from1
whom permission would be sought for dispensation from the doctrines
espoused in the Holy Qur’aanx.
challenges for Muslims. Traditional gender divisions can
lead to worry and consternation about male carers
carrying out physical examinations and physiotherapy
on females, or stays on mixed-sex wards. These situa-
tions must be handled with great diplomacy if anxieties
are to be reduced and compromises reached.
For those whose lung function has deteriorated to the
point where transplantation is considered, again views
about organ donation and blood products will need to
be considered. Spending time on developing good rela-
tions and understanding and respecting cultural differ-
ences, will pave the way for effective discussion and
adaptation.
2.4. Care the dying and death
Most religions have strict and specific funeral rituals,
however, only some have guidelines for care during the
process of dying. As with all patients, open discussion
with them and their relatives about their wishes must
take place. However, for certain groups, (e.g. Jews and
Muslims), operational policies exist within most NHS
Trusts which address how death in normal and abnormal
circumstances, autopsy and burials, should be followed
whenever possible.
Muslims with CF who are dying should be made to
sit or lie facing the Qiblah (the first house of worship
in Mecca) if possible. Family members should be
permitted to recite prayers around their relative’s bed
even if this is situated in a bay.
After death, there are explicit instructions about how
the body should be handled and released, with burial
taking place as soon as possible after death. The body
of a Jewish patient who dies must be handled with equal
care and most NHS Trust protocols include how teams
should respond during the Sabbath and other religious
festivals and holidays.
3. Conclusions
Different cultures present different challenges in man-
aging CF. Increased screening programmes and the
identification of new genetic CFTR mutations will lead
to an increased understanding of CF in non-Caucasian
populations and maybe the recognition of a higher
incidence. In the UK, although current numbers of non-
Caucasian CF patients are relatively small, when aggre-
gated throughout the country, they represent sizeable
groups. The challenges in managing such patients are to
consider developing and maintaining good therapeutic
relationships, improving patient-education and negotiat-
ing certain aspects of treatment. To date most studies of
ethnic diversity in CF have focused on screening and
incidence. Very few have explored the experiences of
such groups and how CF impacts on their lives. There
is a real need to understand more about this, particularly
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with increasing knowledge of identification and possible
incidence.
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